Clinical Trial Search

Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Overall Survival — 0; 0 Proportion of participants

Primary: Frequency of Observed Adverse Events (AEs) — 100; 100; 100; 100 percentage of participants

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: Locoregional Failure Rate at 3 Years — 42; 20 percentage of participants

Primary: Number of Cancers in People With HIV (PWH) Who Present for Care at Domestic AMC Sites — 43; 0; 35; 87 Participants

Primary: Best Response During the Treatment Period — 1; 3; 5; 7 participants

Primary: Number of Participants With Positive Viral Infection — 19; 197; 71; 34 Participants

Primary: Percentage of Participants That Achieved an Objective Confirmed Complete or Partial Overall Tumor Response — 31; 7.7 percentage of participants

Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants

Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877

Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350

Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons

Primary: Occurrence of ≥ Grade 3 Adverse Events Probably or Definitely Related to the Vaccine — 0 participants

Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: Overall Response Rate — 0.577 proportion of participants

Primary: Tolerability of Treatment as Measured by Number of Participants With Grade 3 or Higher Adverse Events — 1; 1; 1; 2 participants

Primary: Number of Participants With Complete Response — 1; 3 participants

Primary: Neoadjuvant: Number of Participants With Drug-Related Select Adverse Events (AEs) — 3; 4; 3; 0 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…

Primary: Treatment Completion Rate — 37 Participants

Primary: Overall Survival (OS) at 1 Year — 1.0; 0.82 Cumulative proportion surviving at 1 yr

Primary: Prevalence of Abnormal Cervical Cytology — 12 Participants

Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911

Primary: Complete Response Through 1 Year — 38; 16 participants

Primary: Overall Survival (OS) — 87.3; 82 percentage of participants

Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg

Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112